SHR1701

DRUG4 trials

Sponsors

Fudan University, Chinese PLA General Hospital, Shandong Cancer Hospital and Institute, The First Affiliated Hospital of Zhengzhou University

Conditions

Advanced Gastric CancerBreast CancerLymphomaMetastatic CancerNon-Small-Cell Lung CancerSHR1701Solid Tumor

Phase 1

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Chinese PLA General HospitalLymphoma, Solid Tumor

Start: 2020-09-01End: 2025-12-01Target: 100Updated: 2023-12-12

Phase 2

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Fudan UniversityBreast Cancer, Metastatic Cancer

Start: 2020-05-01End: 2025-04-01Target: 319Updated: 2022-07-26

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Shandong Cancer Hospital and InstituteNon-Small-Cell Lung Cancer

Start: 2020-09-30End: 2022-12-31Target: 15Updated: 2020-09-23

PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer

RecruitingNCT07294664

The First Affiliated Hospital of Zhengzhou UniversityAdvanced Gastric Cancer, SHR1701

Start: 2025-06-15End: 2028-07-15Target: 36Updated: 2025-12-19

Related Papers

Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial

Cancer Research2024-05-02

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

Journal of Clinical Oncology2023-06-014 citations